Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2021 13:00 ET | Source: Carrick Therapeutics Ltd.

Carrick Therapeutics Presents Encouraging Clinical Data for Samuraciclib (CT7001) at the 2021 San Antonio Breast Cancer Symposium

DUBLIN, Ireland and BOSTON, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies,...
November 22, 2021 08:00 ET | Source: Carrick Therapeutics Ltd.

Carrick Therapeutics to Present Clinical Data on Samuraciclib (CT7001), a First-In-Class Inhibitor of CDK7, at the 2021 San Antonio Breast Cancer Symposium

DUBLIN, Ireland and BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today...
September 16, 2021 07:00 ET | Source: Carrick Therapeutics

Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT-7001) in Combination with Fulvestrant in Advanced HR+, HER2- Breast Cancer Patients at ESMO Congress 2021

Phase 2a Tolerability and Efficacy Data Supports Further Clinical Development of Samuraciclib in Combination with Fulvestrant in HR+, HER2- Breast Cancer Previously Treated with a CDK4/6 Inhibitor ...
August 17, 2021 07:10 ET | Source: Carrick Therapeutics

Carrick Therapeutics to Present First Clinical Data on Samuraciclib (CT-7001), a First-In-Class Inhibitor of CDK7 at the European Society for Medical Oncology (ESMO) Congress 2021

DUBLIN, Ireland and BOSTON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today...
August 16, 2021 08:57 ET | Source: Carrick Therapeutics

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2ꟷ Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer

DUBLIN, Ireland and BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today...
August 16, 2021 07:00 ET | Source: Carrick Therapeutics

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2- Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer

DUBLIN, Ireland and BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today...
August 02, 2021 08:30 ET | Source: Carrick Therapeutics

Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer

DUBLIN, Ireland and BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today...